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Describing global pediatric RSV disease 
at intensive care units in GAVI-eligible countries 
using molecular point-of-care diagnostics: 
the RSV GOLD-III study protocol
Yvette N. Löwensteyn1, Natalie I. Mazur1, Harish Nair2,3, Joukje E. Willemsen1, Ghislaine van Thiel4 and 
Louis Bont1,3*  on behalf of the RSV GOLD III—ICU Network study group 
Abstract 
Background: Respiratory syncytial virus (RSV) infection is an important cause of hospitalization and death in young 
children. The majority of deaths (99%) occur in low- and lower-middle-income countries (LMICs). Vaccines against 
RSV infection are underway. To obtain access to RSV interventions, LMICs depend on support from Gavi, the Vaccine 
Alliance. To identify future vaccine target populations, information on children with severe RSV infection is required. 
However, there is a lack of individual patient-level clinical data on instances of life-threatening RSV infection in LMICs. 
The RSV GOLD III—ICU Network study aims to describe clinical, demographic and socioeconomic characteristics of 
children with life-threatening RSV infection in Gavi-eligible countries.
Methods: The RSV GOLD-III—ICU Network study is an international, prospective, observational multicenter study 
and will be conducted in 10 Gavi-eligible countries at pediatric intensive care units and high-dependency units 
(PICUs/HDUs) during local viral respiratory seasons for 2 years. Children younger than 2 years of age with respiratory 
symptoms fulfilling the World Health Organization (WHO) “extended severe acute respiratory infection (SARI)” case 
definition will be tested for RSV using a molecular point-of-care (POC) diagnostic device. Patient characteristics will be 
collected through a questionnaire. Mortality rates of children admitted to the PICU and/or HDU will be calculated.
Discussion: This multicenter descriptive study will provide a better understanding of the characteristics and mortal-
ity rates of children younger than 2 years with RSV infection admitted to the PICU/HDU in LMICs. These results will 
contribute to knowledge on global disease burden and awareness of RSV and will directly guide decision makers in 
their efforts to implement future RSV prevention strategies.
Trial registration number: NL9519, May 27, 2021
Keywords: Respiratory syncytial virus, Children, Pediatric intensive care unit, Study design, Lower-middle-income 
countries, Burden, Awareness
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Background
Respiratory syncytial virus (RSV) infection is an impor-
tant cause of hospitalization and mortality due to lower 
respiratory tract infection (LRTI) in children under 
5  years of age worldwide [1]. Annual RSV-related hos-
pital admissions and in-hospital deaths in this age group 
have been estimated to be 3.2 million and 59,600, respec-
tively, while overall annual RSV-related mortality includ-
ing community deaths could be as high as 118,200 [1]. 
The majority of deaths (99%) occur in low- and lower-
middle-income countries (LMICs) due to lack of access 
to healthcare and poor quality of care in health facilities 
[1], and children under 2 years of age are disproportion-
ally affected [2, 3]. As the Haemophilus influenza type 
b and pneumococcal conjugate vaccines are introduced 
and scaled up in LMICs, the global burden of child pneu-
monia attributable to bacterial causes has decreased and 
the proportional contribution of viral pathogens has 
increased. RSV now remains one of the major pathogens 
that needs to be tackled in order to achieve sustainable 
development goal 3.2—end preventable deaths of new-
borns and children under 5 years of age by 2030.
Currently there is no immunization available against 
RSV, although several vaccine and monoclonal antibody 
candidates are under clinical development [4]. The most 
advanced maternal vaccine candidate has completed a 
phase 3 trial but did not meet the primary endpoint [5]. 
A new extended half-life monoclonal antibody developed 
by SanofiPasteur / MedImmune, nirsevimab (previously 
MEDI8897), has met the primary endpoint of reducing 
RSV LRTI in healthy infants in a recent phase III trial [6].
Gavi, the Vaccine Alliance (previously: Global Alliance 
for Vaccines and Immunizations), is an international 
organization that invests in vaccines to protect children’s 
lives and health in LMICs. Every 5 years, Gavi develops a 
new vaccine investment strategy (VIS) to prioritize new 
and under-used vaccines and to make these available to 
LMICs through the Gavi vaccine support programme. 
RSV interventions, including both maternal vaccine and 
monoclonal antibodies, were considered as one of the 
six prioritized vaccine programmes as part of Gavi VIS 
for the 2021–2025 funding period [7]. It is anticipated 
that future RSV vaccines or monoclonal antibodies will 
be most efficacious in targeting severe disease leading to 
poor outcome (e.g. oxygen supplementation, ICU admis-
sion, and death).
The majority of Gavi-eligible countries have sparse or 
no individual patient-level data to make decisions on 
target populations for RSV interventions when these 
become available in the next 5–10 years. These data will 
be important for cost-effectiveness analyses of potential 
RSV interventions to assist policy makers in making deci-
sions related to resource allocation for RSV interventions 
[8]. Patient-data will also contribute to local disease 
awareness. Defining burden in terms of RSV incidence 
and case-fatality ratios in Gavi-eligible countries has 
been challenging due to insufficient diagnostic capabili-
ties for RSV surveillance [9]. Interviews with stakehold-
ers revealed that RSV prevention received low priority at 
national and government level due to lack of information 
about disease and disease burden, and some respondents 
suggested that RSV diagnostics would help to improve 
value proposition [10].
This study aims to obtain individual patient-level data 
from children who have been admitted with severe RSV 
infection at the (pediatric) intensive care unit (ICU) or 
high-dependency unit (HDU) in Gavi-eligible countries 
through implementation of RSV point-of-care testing to 
pave the way for future vaccine introduction.
Methods/design
Study design and study site selection
The RSV GOLD III study is a prospective, observational, 
multi-centre study and will be conducted at 11 sites in 
10 Gavi-eligible countries. The study was initiated at the 
first study sites in April, 2021. The total duration of the 
study is 2 years for each participating study site. To select 
study sites, we sent out an open invitation for collabora-
tion to researchers and physicians from various LMICs 
from the existing RSV GOLD network. Before the start of 
the study, we collected information about potential study 
sites through email correspondence and teleconferences. 
The minimum collected information included but was 
not limited to the location and catchment area of the hos-
pital, the hospital staff to be in charge of performing the 
study, logistics of the hospital (languages spoken, freezer 
availability, respiratory seasonality), pediatric ward, pedi-
atric or neonatal ICU, and (pediatric) HDU availability 
and number of beds, the annual number of respiratory 
illness-related admissions, and mortality rates. If admis-
sion data were not available, estimations were made by 
the study team based on number of beds and information 
from local collaborators. We selected study sites based on 
a high expected number of RSV inclusions, quality of the 
communication and engagement of local collaborators.
Study sites
The study will be conducted in the following LMICs: 
Afghanistan, Cameroon, Ghana, Haiti, Mozambique, 
Nepal (2 hospitals), Nigeria, Sudan, Tanzania, and The 
Gambia. The study will also be conducted at 2 sites in the 
Netherlands to allow for a comparison of patient charac-
teristics with patients from a high-income country (HIC). 
Table  1 provides the characteristics of the participating 
LMIC study sites.
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Study objectives
Primary objective
To describe the clinical, demographic, and socioeco-
nomic characteristics of RSV-positive children under 
2  years of age who have been admitted with sus-
pected RSV infection at ICUs or HDUs in Gavi-eligible 
countries.
Secondary objectives
1. To determine proportional RSV-related mortality in 
children under 2 years of age at participating ICUs or 
HDUs.
2. To compare clinical, demographic, and socioeco-
nomic characteristics between children with fatal 
and non-fatal RSV infection.
3. To compare clinical, demographic, and socioeco-
nomic characteristics between children with RSV 
infection from LMICs and HICs.
4. To describe RSV seasonality in the study locations.
5. To compare clinical, demographic, and socioeco-
nomic characteristics between children with (fatal) 
RSV infection and children with (fatal) influenza 
infection.
6. To confirm the point-of-care (POC) RSV test using 
conventional or real-time RSV PCR.
7. To estimate the sensitivity of the World Health 
Organization (WHO) “extended severe acute respira-
tory infection (SARI)” case definition for hospital-
based surveillance for severe RSV infection. [11]
8. To compare the burden of RSV infection and mortal-
ity rates between children who do and do not meet 
the WHO “extended SARI” case definition.
Study participants
For this study, 2 different groups of children (A and 
B) are distinguished. For each group, a subject must 
meet all the eligibility criteria in order to participate 
(Table  2). Children from group A will be tested for 
RSV at all study sites and for influenza at 3 study sites 
(Ghana, Mozambique, Nepal) (Fig. 1):
Group A. Children with suspected RSV disease (all study sites)
1. Children < 2 years of age at time of sampling;
2. Who are admitted to an ICU and/or HDU and meet 
the WHO “extended SARI” case definition;
Table 1 Characteristics of the participating RSV GOLD III - ICU Network study sites in low- and lower-middle-income countries
PICU pediatric intensive care unit, HDU high dependency unit, NICU neonatal intensive care unit, NA not available
*Emergency unit serves as HDU
**No recruitment






Estimated annual number 
of children < 2 years 
admitted to PICU / HDU 
/ NICU with severe acute 
respiratory infection
Respiratory season
Zaria, Nigeria Ahmadu Bello University 
Teaching Hospital
NA 32* 8 155 April–November
Mazar-e-Sharif, Afghanistan Balkh regional hospital 35 NA 8 650 October–March
Banjul, The Gambia Edward Francis Small Teach-
ing Hospital
NA 20 37 100 October-May
Khartoum, Sudan Jafar Ibn Auf Specialized 
Hospital for Children
8 9 16 100 December-May
Kathmandu, Nepal Kanti Children’s Hospital 12 8 16 130 July-March
Kathmandu, Nepal Tribhuvan University Teach-
ing Hospital
4 6 8 32 July-March
Douala, Cameroon Laquintinie Hospital Douala 20 NA NA 180 September-January
April-June
Accra, Ghana Korle Bu Teaching Hospital 6 18 50** 70 June-November
Maputo, Mozambique Maputo Central Hospital 21 NA 70** 85 March-August
Dar es Salaam, Tanzania Muhimbili National Hospital 13 NA 19** 270 December-May
Port-au-Prince, Haiti Saint-Damien Hospital 10 NA 16** 40 August-January
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Children who do not meet the WHO “extended 
SARI” case definition will be tested for RSV at 3 study 
sites (group B):
Group B. Children who are not suspected to have RSV disease 
(Ghana, Mozambique, Nepal)
1. Children < 2 years of age at time of sampling;
2. Who are admitted to an ICU and/or HDU and do 
not meet the WHO “extended SARI” case definition;
WHO “extended SARI” RSV surveillance case definition
In this study, the global case definition developed by the 
WHO for hospital-based RSV surveillance is used to iden-
tify children hospitalized with suspected RSV infection. 
The RSV surveillance case definition was recently modi-
fied based on results from the WHO RSV surveillance pilot 
which showed that the use of an extended SARI case defini-
tion, not requiring fever to identify a suspect case, substan-
tially increased the number of RSV infections detected [3].
In group A, subjects will be tested for RSV when they are 
admitted to the ICU meeting the WHO “extended SARI” 
case definition for hospital-based surveillance for severe 
RSV infection:
• Severe (defined as requiring hospitalization); and
• Acute (defined as onset within the last 10 days); and
• Respiratory infection (defined as having cough or 
shortness of breath)
In infants less than 6  months, additionally include 
those who present with:
• Apnea (temporary cessation of breathing from any 
cause); and/or
• Sepsis, defined as:
• Fever (37.5  °C or above) or hypothermia (less than 
35.5 °C); and
• Shock (defined as lethargy, fast breathing, cold skin, 
prolonged capillary refill or fast weak pulse); and
• Seriously ill with no apparent cause
In group B subjects not fulfilling the WHO “extended 
SARI” case definition will also be tested for RSV.
Exclusion criteria
Neonates younger than 4 days old will not be tested for 
RSV or influenza due to the high incidence of respiratory 
symptoms related to intrapartum-related complications 
or prematurity in this group.
Sample collection
A nasopharyngeal swab (flocked swab, COPAN, 3  ml 
universal transport medium (UTM)) will be obtained as 
soon as possible but no later than 72 h after admission to 
the PICU and/or HDU. Samples will be taken by trained 
healthcare staff.
Table 2 Eligibility criteria for RSV GOLD III—ICU Network Study
PICU pediatric intensive care unit, HDU high dependency unit, NICU neonatal intensive care unit, WHO world health organization, SARI severe acute respiratory 
infection
Inclusion criteria
Group A Group B
Age < 2 years at time of sampling;
Admitted to PICU / HDU / NICU;
Meeting WHO “Extended SARI” case definition:
Severe (defined as requiring hospitalization); and
Acute (defined as onset within the last 10 days); and
Respiratory infection (defined as having cough or shortness of breath)
In infants less than 6 months, additionally include those who present with:
Apnea (temporary cessation of breathing from any cause); and/or
Sepsis, defined as:
Fever (37.5 °C or above) or hypothermia (less than 35.5 °C); and
Shock (defined as lethargy, fast breathing, cold skin, prolonged capillary 
refill or fast weak pulse); and
Seriously ill with no apparent cause
Signed and dated written informed (deferred) consent obtained from the 
parent(s)/legal representative(s) of the subject, or in accordance with 
local regulations
Age < 2 years at time of sampling;
Admitted to PICU / HDU / NICU;
Signed and dated written informed (deferred) consent obtained from the 
parent(s)/legal representative(s) of the subject, or in accordance with 
local regulations
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Point‑of‑care testing
The samples will be tested for RSV and influenza using 
the highly sensitive and specific point-of-care (POC) ID 
NOW test [12–14]. On-site training for local study staff 
on performing the POC test will be provided by the RSV 
GOLD team. If site visits are not possible, the training 
will be given online. Refresher training will be provided 
before the start of each new respiratory season or if 
required by the study sites.
Point‑of‑care test confirmation
Although the POC ID NOW RSV test has shown high 
sensitivity and specificity of 100% and 97%, respectively, 
in previous studies [13], polymerase chain reaction 
(PCR) remains the gold standard for confirmation of a 
positive or negative test. POC RSV test confirmation is 
an optional part of the protocol. Samples will preferably 
be shipped to the University Medical Centre Utrecht 
(UMCU) laboratory for conventional or real-time PCR 
testing in order to confirm the POC RSV test and ensure 
Fig. 1 Schematic diagram of the study workflow. Group A: children < 2 years admitted to the PICU and/or HDU meeting the WHO “extended SARI” 
case definition (10 study sites). Group B: children < 2 years admitted to the PICU and/or HDU not meeting the WHO “extended SARI” case definition 
(3 study sites: Ghana, Mozambique, Nepal)
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quality of the data. Researchers may decide to perform 
viral testing and/or sequencing at a local, national or 
academic reference laboratory accredited to interna-
tional quality standards with validated conventional or 
real-time RSV PCR tests when the capacity is available or 
when shipment of samples to UMCU is not possible.
Per study site, the following samples will be confirmed:
• All RSV-positive samples.
• A matched (by age and month of admission) number 
of RSV-negative samples.
Sample storage
Nasopharyngeal samples will be stored in freezers before 
shipment. For budget restrictions, influenza-positive 
samples will not be confirmed through PCR and will not 
be stored.
RSV sequencing
RSV sequencing is an optional part of the protocol. Sam-
ples sent for confirmation will be stored at the UMCU or 
study site to allow for sequencing if the sample is RSV-
positive. Investigating the molecular heterogeneity of 
RSV isolates can be important to determine susceptibil-
ity or resistance to future RSV monoclonal antibodies or 
vaccines.
Data collection and data management
From each study site baseline data will be obtained using 
questionnaires to evaluate local clinical treatment and 
management availability and standards. Included patients 
will be followed up until death or discharge. Participant 
data will be collected through a case report form and 
parental questionnaire (Additional file 1: Table S1). These 
data will be entered by hospital study staff into Castor 
Electronic Data Capture (EDC) system [15]. Data valida-
tion, data analysis and interpretation of the data will be 
performed by the Utrecht-based study team in collabora-
tion with the site investigators.
Sample size
RSV
The aim is to include all children < 2 years of age meeting 
the case definition admitted to the PICU and/or HDU at 
each study site each year during the respiratory season. 
There is no maximum number of patients each study site 
needs to recruit. We estimated the following number of 
inclusions for all study sites (Table 3):
Group A
Based on an estimated number of admissions, we expect 
to recruit 2800 patients across 10 study sites, 100–400 
patients at each study site. Assuming 30% of patients who 
fulfill the WHO case definition “extended SARI” will have 
a positive RSV test, we expect to capture 840 RSV-posi-
tive children, 30–120 children at each study site. Assum-
ing a mortality rate of 10% we expect approximately 3–12 
RSV-related deaths at each study site, in total N = 84 
deaths. We consider this number sufficient for descrip-
tive purposes.
If 2800 patients will be recruited and 30% RSV-pos-
itives are observed (N = 840), this produces a two-sided 
95% Clopper-Pearson confidence interval with a width 
equal to 0.034, ranging from 28 to 32%. In the smallest 
estimate, 100 patients will be recruited per site. With an 
assumed RSV-positive sample proportion of 30%, a sam-
ple size of 100 patients produces a two-sided 95% confi-
dence interval with a width equal to 0.187, with a lower 
limit of 21% and an upper limit of 40%.
In 840 RSV-positive patients, an observed proportion 
of mortality of 10% will produce a two-sided 95% confi-
dence interval with a width equal to 0.042, producing a 
lower limit of 8.1% and an upper limit of 12.2%. In the 
smallest estimate, 100 patients will be recruited per site. 
With an observed mortality proportion of 10%, a sample 
size of 100 patients produces a two-sided 95% confidence 
interval with a width equal to 0.127, corresponding to a 
lower limit of 4.9% and an upper limit of 17.6%. We con-
sider those estimates sufficiently precise.
Group B
We expect to recruit 1200 patients in 3 study sites, 200–
600 patients at each study site. Assuming 5% of patients 
will have a positive RSV test, we expect to capture 60 
RSV-positive children, 10–30 children at each study 
site. Assuming a mortality rate of 10% in children who 
tested positive for RSV, we expect an additional 1–3 RSV-
related deaths at each study site, in total N = 6 deaths.
When the sample proportion is 5%, a sample size of 
1200 patients produces a two-sided 95% confidence 
interval with a width equal to 0.026, corresponding to a 
confidence interval from 3.8 to 6.4%.
In 60 RSV-positive patients, an observed propor-
tion of mortality of 10% will produce a two-sided 95% 
Table 3 Estimated number of RSV-positive patients and RSV-
related deaths
RSV‑positive patients 







Group A 30–120 840 84
Group B 10–30 60 6
Total NA 900 90
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confidence interval with a width equal to 0.167, with a 
lower limit of 3.8% and an upper limit of 20.5%.
Sensitivity WHO case definition
The sensitivity of the WHO “extended SARI” case defini-
tion will be calculated using the total population from the 
3 sites that included group A and B for RSV testing. In 
total, we expect to recruit 800 patients from group A and 
1200 patients from group B at 3 study sites, in total 2000 
patients. We will not adapt the sample size for this pur-
pose as this is a secondary endpoint of the study.
Influenza (secondary objective)
Per site we expect to test for influenza in 100–400 (group 
A) children. Assuming a 5% positivity rate we expect to 
capture 42 influenza-positive children, 5–20 children 
at each study site. Assuming a mortality rate of 10%, we 
expect approximately 1–2 influenza-related deaths at 
each study site for group A, in total N = 4 deaths.
Statistical analysis
We will describe characteristics of RSV-positive chil-
dren. Chi-square tests and nonparametric tests will be 
used to compare clinical and demographic characteristics 
between children where appropriate. RSV-positive chil-
dren from group A and group B will be presented as pro-
portions with 95% confidence intervals. The estimated 
case fatality ratio in RSV positive children will be pro-
vided with 95% confidence intervals. We will also report 
the mortality rate with 95% confidence intervals, and 
total RSV-related mortality in group A and B. Subgroup 
analysis per site will also be performed. We will calcu-
late the sensitivity of the WHO case definition “extended 
SARI”. We will divide the number of RSV-positive chil-
dren meeting the case definition (group A) by the total 
number of RSV-positives regardless of whether the case 
definition was met and express it as a percentage. No for-
mal statistical analysis plan was written before the start 
of this descriptive study.
Burden of disease
The estimated number of RSV-related PICU and/or 
HDU admissions and deaths in children with respira-
tory infection in the specific country of participating 
study sites will be quantified. A numerator (the number 
of POC-confirmed RSV-related admissions and deaths at 
the PICU and/or HDU) and denominator (population in 
the hospital catchment area) will be defined. In case the 
catchment population is not readily available because the 
facility is not the only one providing in-patient care to the 
population, it will be estimated based on reviewing hospi-
tal administrative datasets and using a hospital admission 
survey [16]. In the case of limited administrative data or 
limited resources to perform a hospital admission survey, 
burden of RSV disease may be described in terms of the 
proportion of RSV-related PICU and/or HDU admissions 
(or deaths) among all PICU and/or HDU admissions 
with LRTI. Other markers of disease burden will also be 
reported, such as length of stay, duration of oxygen sup-
plementation, etc.
Ethical considerations
The study will be conducted according to the principles 
of the Declaration of Helsinki (version 2013), and local 
law and regulations. Risks and burdens for study sub-
jects are considered minimal. No other safety issues are 
expected due to the set-up and nature of the study. No 
Data Safety Monitoring Board will be appointed and 
no (Severe) Adverse Events will be reported. Written 
informed consent will be obtained from each patient-
participant by research staff or in accordance with local 
regulations prior to enrolment in the study.
The intended benefits resulting from this study can be 
divided into 1) direct benefits and 2) indirect benefits. 
The primary direct benefit for study participants is timely 
and proper diagnosis of RSV infection which may result 
in the prevention of unnecessary or inappropriate use of 
antibiotics. Secondary direct (patient) benefits consist of:
a) The ability to determine that RSV is not the cause of 
disease and that an alternative diagnosis should be 
considered in case of a negative test;
b) The ability to provide parents of RSV-positive chil-
dren who have been admitted to PICU and/or HDU 
or who died with information about the cause of or 
contribution to death.
Indirect (societal) benefits consist of:
a) The ability to provide information on disease burden 
and target populations to policy makers when a vac-
cine becomes available;
b) Giving medical staff insights into the incidence of 
RSV/influenza-related admissions and mortality at 
their hospital;
c) Identifying RSV and influenza as important causes of 
PICU and/or HDU admission and death;
d) Capacity building by supplying a reliable POC test to 
confirm or rule out RSV and influenza as a cause of 
respiratory infection;
e) Capacity building through involving local site investi-
gators in conducting clinical research;
f ) Increasing overall RSV awareness of hospital staff 
and parents of young children.
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For children from HICs, no direct benefits apply, as 
RSV testing is part of routine care.
Dual ethical review was performed to ensure that the 
ethical standards in this study are no less stringent than 
those applicable in the country of the sponsoring organi-
zation. This protocol was therefore submitted for ethics 
review in The Netherlands as well as to all local (and/or 
national) research ethics committees.
Discussion
Although global estimates show a high RSV burden in 
children from LMICs, individual patient-level data are 
lacking due to limited availability of RSV testing in these 
countries. The critical lack of diagnostic capacity ham-
pers the ability to distinguish RSV from other causes 
of severe respiratory infection in children to justify the 
need for vaccine introduction in LMICs. Disease aware-
ness is essential to introduce RSV interventions, which 
will become available in the near future. RSV GOLD is 
the first global online registry for children younger than 
5 years who have died with RSV infection. The first results 
of the RSV GOLD study have been previously published 
[2, 17]. The registry was extended after publication (RSV 
GOLD II) and data collection is still ongoing. In order to 
increase real-time data collection from LMICs, funding 
was obtained to establish a network of PICUs in 10 differ-
ent Gavi-eligible countries (RSV GOLD III).
The RSV GOLD III—ICU Network study is a novel 
collaboration between RSV GOLD and 10 study teams 
from 3 different continents, aiming at collecting indi-
vidual patient-level data of young children with severe 
RSV infection through POC RSV testing. Data analyses 
will provide insights into potential risk factors for fatal 
RSV infection at the PICU and/or HDU and differences 
between patients from various income settings.
Some challenges remain for this type of study. First, 
this study will take place mainly in tertiary level facilities 
in urban areas where access to healthcare is likely better 
than in rural areas. Results may therefore not be repre-
sentative of the whole country. Second, the definition of 
an ICU and HDU may differ from country to country and 
even within a single healthcare system. For example, in 
some countries, the capacity to mechanically ventilate 
differentiates a PICU bed from a HDU bed, while in other 
countries, a PICU bed may be defined as a bed within a 
hospital area with a higher patient: nurse ratio. In 2017, 
the task force of The World Federation of Societies of 
Intensive and Critical Care Medicine proposed a global 
definition and stratified ICUs based on the intensity 
of care provided [18]. For this study, we included both 
PICUs and HDUs according to the definition of the par-
ticipating study sites, where the most severely ill children 
are usually admitted. To characterize differences between 
participating PICUs and HDUs, we will collect informa-
tion on the capacity of care, such as the number of avail-
able ventilators and attending healthcare staff. Third, due 
to budgetary constraints, we are unable to extend RSV 
testing to the regular wards. We will therefore likely miss 
a proportion of potential study participants in case PICU 
and/or HDU beds are occupied and children with severe 
respiratory infection are admitted to the regular wards 
instead. We will make an effort in collecting informa-
tion on the number of refusals to estimate the potential 
impact of this study limitation. Also, influenza testing is 
limited to 3 study sites. However, this study will provide 
insights into the characteristics of hospitalized children 
with severe RSV infection in LMICs including complete 
granular age distribution data which can be used for 
modelling studies on the impact of upcoming mater-
nal vaccines and monoclonal antibodies against RSV. 
Fourth, for some study sites it may be difficult to calcu-
late a catchment population due to the presence of other 
PICUs in the area. We will collect information on the 
number of other available PICUs and will adjust for this 
in our calculations. Based on preliminary data we esti-
mate that 2–4 study sites will not have sufficient data to 
estimate the catchment population.
Finally, the SARS-CoV2 pandemic may affect the num-
ber of respiratory admissions, thus study results may 
not be representative of regular respiratory seasons in 
participating countries. Since the duration of the study 
is 2 years and most of the recruitment will take place in 
2022, we do not expect this to be a major limitation.
In summary, this global prospective multicenter study 
will provide a better understanding of the characteristics 
and mortality rates of children younger than 2 years who 
are admitted to the PICU and/or HDU with severe RSV 
infection in LMICs. These results will not only contribute 
to knowledge on global disease burden and awareness of 
RSV, but will also provide valuable information to health-
care policy makers on the impact of future RSV preven-
tion strategies.
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